We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+1.08%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.37B
AUM Growth
+$113M
Cap. Flow
+$184M
Cap. Flow %
13.39%
Top 10 Hldgs %
57.14%
Holding
78
New
18
Increased
12
Reduced
20
Closed
17

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$69.7M
2
ABBV icon
AbbVie
ABBV
+$66.1M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$52.5M
4
SYK icon
Stryker
SYK
+$43M
5
REPL icon
Replimune Group
REPL
+$37.7M

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$86.5M
2
ELAN icon
Elanco Animal Health
ELAN
+$51.7M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$19.3M
4
COGT icon
Cogent Biosciences
COGT
+$14.4M
5
INCY icon
Incyte
INCY
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
76
TG Therapeutics
TGTX
$8.53B
– –
-358,644
Closed -$8.39M
TMO icon
77
Thermo Fisher Scientific
TMO
$208B
– –
-5,770
Closed -$3.57M
MRNS
78
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-4,386,177
Closed -$7.72M
1 2 3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2024 Portfolio in Review

As of Q4 2024, Sofinnova Investments held 78 positions worth $1.37B, up 9% from $1.26B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sofinnova Investments deployed $184M of net new capital in Q4 2024, opening 18 new positions and adding to 12 existing holdings. Its largest new stake was Gilead Sciences: 774,227 shares worth $71.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was IDEAYA Biosciences, an estimated $19.3M trimmed.

  • Sofinnova Investments's largest Q4 2024 buy was Gilead Sciences: 774,227 shares worth $71.5M.
  • Sofinnova Investments added most to Replimune Group in Q4 2024, an estimated $37.7M increase.
  • Sofinnova Investments's biggest Q4 2024 reduction was IDEAYA Biosciences, cutting an estimated $19.3M.
  • Sofinnova Investments fully exited Novo Nordisk in Q4 2024, selling an estimated $86.5M.
  • Sofinnova Investments's ten largest holdings make up 57% of its $1.37B portfolio in Q4 2024.
  • Sofinnova Investments opened 18 new positions and closed 17 in Q4 2024.
  • Sofinnova Investments's portfolio value rose 9% quarter-over-quarter to $1.37B.

Based on Sofinnova Investments's 13F filing for Q4 2024, filed 14 Feb 2025.